Metabolon Receives CLIA Certificate of Registration
News Mar 18, 2011
The CLIA registration allows Metabolon’s clinical laboratory to perform high-complexity tests on patient samples. Later this year, the company plans to launch tests for insulin resistance and urological cancers based upon biochemical biomarkers the company discovered using its proprietary metabolomic profiling technology platform.
John Ryals, Metabolon’s president and chief executive officer said, “CLIA certification is an important step in our strategy to derive further economic value from our sophisticated approach to biomarker discovery while advancing our plans to fulfill the promise of personalized medicine.”
Researchers at the University of Arizona have completed the first-of-its-kind study that could aid in the treatment, diagnosis and prevention of cervical cancer by identifying cervicovaginal metabolic signatures, or "fingerprints" that distinguish patients with HPV, pre-cancerous cervical conditions and cancer.READ MORE
Regardless of how much you exercise or how balanced your diet is, controlling your weight is more brain-related than you might have thought. In a recent study, researchers show for the first time in mice that the acyl-CoA-binding protein, or ACBP, has a direct influence on the neurons that allow rodents and humans to maintain a healthy weight.READ MORE